Invention Title:

CHIMERIC RECEPTORS

Publication number:

US20260306631

Publication date:
Section:

Human necessities

Class:

A61K40/31

Inventors:

Assignee:

Applicant:

Smart overview of the Invention

Chimeric receptors composed of homodimeric polypeptides are the focus, with significant applications in tumor immunotherapy, particularly adoptive cell therapy. These receptors enhance immune responses against target antigens by genetically modifying therapeutic immune cells. The patent discusses therapeutic cells expressing these chimeric receptors and outlines methods for treating patients using these modified cells.

Technical Composition

The chimeric receptor is a homodimer consisting of two polypeptide monomers, each with three key regions:

  • Extracellular Region: Contains homodimerizing motifs, such as leucine zipper motifs, which may include ligand-dependent motifs like FKBP12F36V.
  • Transmembrane Region: Often derived from cell-surface receptors like EpoR or GHR.
  • Intracellular Region: Houses signaling regions from cell-surface receptors or signal transducing adaptor proteins, activating pathways like JAK-STAT or NFκB.

Functional Enhancements

These receptors address challenges faced by CAR T cells, particularly in solid tumors, by improving persistence without antigen stimulation and functionality amidst chronic antigen exposure. This is achieved by incorporating cytokines like IL-2, IL-7, IL-15, and IL-21, enhancing antitumor activity while managing safety concerns associated with cytokine activation of bystander cells.

Signaling Pathways

The intracellular signaling regions can activate various pathways, including:

  • JAK-STAT pathway
  • NFκB pathway
  • Myddosome-related pathways like IRAK, TRAF, TBK, MAPK, PKB/AKT, and PI3K

These pathways are crucial for robust immune responses, enabling the engineered cells to combat tumors effectively.

Applications and Variations

Chimeric receptors can be tailored with specific signaling regions derived from cytokine receptors or receptor tyrosine kinases, such as EGFR or Toll-like receptors. This flexibility allows for the customization of therapeutic cells to target various cancer types, enhancing the efficacy and safety of immunotherapies.